4.8 Article

Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation

期刊

NATURE CHEMICAL BIOLOGY
卷 18, 期 9, 页码 963-+

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41589-022-01059-7

关键词

-

资金

  1. BC Leadership Chair in Functional Cancer Imaging
  2. Canadian Institute of Health Research grant [FDN154328]
  3. Canada Excellence Research Chair
  4. National Institute of General Medical Sciences from the National Institutes of Health [P30 GM124165]
  5. NIH-ORIP HEI grant [S10OD021527]
  6. DOE Office of Science [DE-AC02-06CH11357]
  7. Boehringer Ingelheim
  8. Bristol Myers Squibb
  9. Genome Canada through Ontario Genomics Institute [OGI-196]
  10. EU
  11. EFPIA through the Innovative Medicines Initiative 2 Joint Undertaking [875510]
  12. Janssen
  13. Merck KGaA
  14. Pfizer
  15. Takeda
  16. Bayer AG
  17. Genentech
  18. Mitacs Accelerate Internship

向作者/读者索取更多资源

This study provides insights into the structure and function of TMPRSS2, a key protein involved in the viral entry and pathogenesis of SARS-CoV-2. By studying its structure and cleavage sites, the researchers also uncovered the specificity of TMPRSS2, which can aid in drug development efforts.
Transmembrane protease, serine 2 (TMPRSS2) has been identified as key host cell factor for viral entry and pathogenesis of SARS-CoV-2. Specifically, TMPRSS2 proteolytically processes the SARS-CoV-2 Spike (S) protein, enabling virus-host membrane fusion and infection of the airways. We present here a recombinant production strategy for enzymatically active TMPRSS2 and characterization of its matured proteolytic activity, as well as its 1.95 angstrom X-ray cocrystal structure with the synthetic protease inhibitor nafamostat. Our study provides a structural basis for the potent but nonspecific inhibition by nafamostat and identifies distinguishing features of the TMPRSS2 substrate binding pocket that explain specificity. TMPRSS2 cleaved SARS-CoV-2 S protein at multiple sites, including the canonical S1/S2 cleavage site. We ranked the potency of clinical protease inhibitors with half-maximal inhibitory concentrations ranging from 1.4 nM to 120 mu M and determined inhibitor mechanisms of action, providing the groundwork for drug development efforts to selectively inhibit TMPRSS2.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据